Galapagos increases share capital through warrant exercises
September 19 2016 - 4:10PM
Galapagos NV (Euronext & NASDAQ: GLPG) announces a share
capital increase arising from warrant exercises.
Galapagos issued 60,320 new ordinary shares on
19 September 2016, for a total capital increase (including issuance
premium) of €603,289.80.
Pursuant to the warrant exercise program of
Galapagos' Executive Committee, Executive Committee members
automatically are committed to exercise a minimum number of
warrants, subject to certain conditions. In accordance with the
rules of this program, CEO Onno van de Stolpe exercised 15,000
warrants and two other Executive Committee members exercised an
aggregate number of 10,000 warrants. In addition to Onno van de
Stolpe, one other Board member exercised 2,520 warrants.
In accordance with Belgian transparency
legislation[1], Galapagos notes that its total share capital
currently amounts to €249,720,553.98, the total number of
securities conferring voting rights is 46,169,828, which is also
the total number of voting rights (the "denominator"), and all
securities conferring voting rights and all voting rights are of
the same category. The total number of rights (warrants) to
subscribe to not yet issued securities conferring voting rights is
3,552,657, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does not have
any convertible bonds or shares without voting rights
outstanding.
About Galapagos Galapagos (Euronext & NASDAQ: GLPG)
is a clinical-stage biotechnology company specialized in the
discovery and development of small molecule medicines with novel
modes of action. Our pipeline comprises Phase 3, 2, 1, pre-clinical
and discovery studies in cystic fibrosis, inflammation, fibrosis,
osteoarthritis and other indications. We have discovered and
developed filgotinib: in collaboration with Gilead we aim to bring
this JAK1-selective inhibitor for inflammatory indications to
patients all over the world. Galapagos is focused on the
development and commercialization of novel medicines that will
improve people's lives. The Galapagos group, including
fee-for-service subsidiary Fidelta, has approximately 460
employees, operating from its Mechelen, Belgium headquarters and
facilities in The Netherlands, France, and Croatia. More
information at www.glpg.com.
Contacts
Investors: |
Media: |
Elizabeth Goodwin |
Evelyn
Fox |
VP IR
& Corporate Communications +1 781 460 1784 |
Director
Communications +31 6 53 591 999 communications@glpg.com |
Paul van der Horst Director IR & Business Development +31 6 53
725 199 |
|
ir@glpg.com |
|
Forward-looking statements This release may
contain forward-looking statements. Such forward-looking statements
are not guarantees of future results. These forward-looking
statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update
any forward-looking statements in this document, unless
specifically required by law or regulation.
[1] Belgian Act of 2 May 2007 on the
disclosure of major shareholdings in issuers whose shares are
admitted to trading on a regulated market
GLPG increases share capital through warrant exercises
http://hugin.info/133350/R/2043161/762726.pdf
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024